Page 2 - Read Online

Topic: Resistance to Cancer Immunotherapy: Mechanisms,
Advances, Challenges and Opportunities

Dr. Michael Lahn, currently serving as the Chief Medical Officer at iOnctura
SA in Geneva, Switzerland, is a distinguished medical professional with a
robust background in oncology. Graduating with a Medical Doctorate from
the University of Mainz in 1990, Dr. Lahn then served as an Assistenzarzt
at Albert-Ludwigs-Universität Freiburg im Breisgau. In 2019, Dr. Lahn
brought over two decades of industry expertise, garnered from Eli Lilly and
Company, AstraZeneca, and Incyte Corporation, to iOnctura. His impactful
career involves shaping the development of diverse molecular entities,
from small molecule inhibitors like the ALK5 inhibitor galunisertib to the
Dr. Michael Lahn successful registration of osimertinib in non-small cell lung cancer (NSCLC).
Passionate about pioneering cancer therapies, Dr. Lahn is equally dedicated
iOnctura SA, Geneva, Switzerland. to mentoring colleagues in the intricate domain of clinical drug development.

Dr. Jordi Rodón is a distinguished expert in early drug development,
biomarker discovery, personalized cancer medicine, and neuro-oncology.
He earned his medical and doctoral degrees from the Universitat Autonoma
de Barcelona. Currently holding the position of Associate Professor in the
Department of Investigational Cancer Therapeutics at The University of
Texas MD Anderson Cancer Center in Houston, TX, Dr. Rodón serves as the
Associate Medical Director in the Department of Institute for Personalized
Cancer Therapy. Additionally, he holds a dual/joint/adjunct appointment as
an Associate Professor in the Department of Genomic Medicine. Dr. Rodón's
commitment to advancing cancer therapeutics is underscored by his role as
Dr. Jordi Rodón the Clinical Co-Director of the Precision Oncology Decision Support Team
Department of Investigational Cancer at MD Anderson. He has also contributed significantly to the academic
Therapeutics, The University of community as the Co-chair of the Clinical Trials Task Force for Cancer Core
Texas MD Anderson Cancer Center, Europe.
Houston, TX, USA.

Professor Tobias Arkenau stands as a distinguished Consultant Medical
Oncologist, renowned for his expertise in Gastrointestinal Cancers, Drug
Development, and Immunotherapy. Graduating with a medical degree from
Hanover Medical School in Germany in 2000, Prof. Arkenau completed his
oncology training at esteemed institutions, including the Royal Marsden
Hospital. Recognized for his substantial research contributions, he earned
a Fellowship from the Royal College of Physicians. He previously held a
professorship at the University of London, and as the founding Medical
Director and Executive Medical Director of the Sarah Cannon Research
Institute UK. Currently holding the position of Chief Medical Officer and
Prof. Hendrik Tobias Arkenau Global Head of Drug Development at Ellipses Pharma, Prof. Arkenau
Drug Development Unit, Sarah continues to contribute significantly to the evolution of cancer care and drug
Cannon Research Institute, London, development. His medical practice encompasses a wide range of cancers,
UK.
with a focus on gastrointestinal and skin cancers.